JP7427597B2 - Ｅｒｂｂ／ｂｔｋ阻害剤 - Google Patents

Ｅｒｂｂ／ｂｔｋ阻害剤 Download PDF

Info

Publication number
JP7427597B2
JP7427597B2 JP2020541535A JP2020541535A JP7427597B2 JP 7427597 B2 JP7427597 B2 JP 7427597B2 JP 2020541535 A JP2020541535 A JP 2020541535A JP 2020541535 A JP2020541535 A JP 2020541535A JP 7427597 B2 JP7427597 B2 JP 7427597B2
Authority
JP
Japan
Prior art keywords
compound
egfr
mmol
chromatography
lcms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020541535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512087A5 (https=
JPWO2019149164A5 (https=
JP2021512087A (ja
Inventor
リー，チェンタオ
ゾウ，ハオ
チュー，ウェイ
シェン，チャンマオ
ワン，ルーミン
リウ，ウェンゲン
チェン，シャン
ツイ，ホンチュン
ヤン，チェンファン
チャン，シャオリン
Original Assignee
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド filed Critical ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Publication of JP2021512087A publication Critical patent/JP2021512087A/ja
Publication of JP2021512087A5 publication Critical patent/JP2021512087A5/ja
Publication of JPWO2019149164A5 publication Critical patent/JPWO2019149164A5/ja
Priority to JP2023180451A priority Critical patent/JP7738619B2/ja
Application granted granted Critical
Publication of JP7427597B2 publication Critical patent/JP7427597B2/ja
Priority to JP2025145276A priority patent/JP2025179139A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Electronic Switches (AREA)
  • Polarising Elements (AREA)
JP2020541535A 2018-01-31 2019-01-28 Ｅｒｂｂ／ｂｔｋ阻害剤 Active JP7427597B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023180451A JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2025145276A JP2025179139A (ja) 2018-01-31 2025-09-02 Ｅｒｂｂ／ｂｔｋ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/074791 2018-01-31
CN2018074791 2018-01-31
CN2018118569 2018-11-30
CNPCT/CN2018/118569 2018-11-30
PCT/CN2019/073355 WO2019149164A1 (en) 2018-01-31 2019-01-28 Erbb/btk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023180451A Division JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤

Publications (4)

Publication Number Publication Date
JP2021512087A JP2021512087A (ja) 2021-05-13
JP2021512087A5 JP2021512087A5 (https=) 2022-02-02
JPWO2019149164A5 JPWO2019149164A5 (https=) 2022-02-02
JP7427597B2 true JP7427597B2 (ja) 2024-02-05

Family

ID=67478612

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020541535A Active JP7427597B2 (ja) 2018-01-31 2019-01-28 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2023180451A Active JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2025145276A Pending JP2025179139A (ja) 2018-01-31 2025-09-02 Ｅｒｂｂ／ｂｔｋ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023180451A Active JP7738619B2 (ja) 2018-01-31 2023-10-19 Ｅｒｂｂ／ｂｔｋ阻害剤
JP2025145276A Pending JP2025179139A (ja) 2018-01-31 2025-09-02 Ｅｒｂｂ／ｂｔｋ阻害剤

Country Status (14)

Country Link
US (2) US11007198B2 (https=)
EP (2) EP4356975A3 (https=)
JP (3) JP7427597B2 (https=)
KR (2) KR20250046340A (https=)
CN (3) CN111587244A (https=)
AU (2) AU2019215538B2 (https=)
CA (1) CA3086616A1 (https=)
DK (1) DK3746424T3 (https=)
ES (1) ES2977484T3 (https=)
MX (2) MX2020007947A (https=)
PT (1) PT3746424T (https=)
RU (2) RU2764069C1 (https=)
TW (1) TWI798334B (https=)
WO (1) WO2019149164A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024010038A (ja) * 2018-01-31 2024-01-23 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ／ｂｔｋ阻害剤

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896597B2 (en) * 2018-01-31 2024-02-13 Dizal (Jiangsu) Pharmaceutical Co., Ltd. ErbB/BTK inhibitors
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
WO2021104305A1 (zh) * 2019-11-26 2021-06-03 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
CN111057021B (zh) * 2019-12-11 2023-05-23 中国药科大学 均三嗪类化合物及其制备方法和用途
US20230137932A1 (en) * 2020-01-07 2023-05-04 Dana-Farber Cancer Institute, Inc. Cyano-pyrimidine inhibitors of egfr/her2
CN111470998B (zh) * 2020-06-28 2020-09-25 上海皓元生物医药科技有限公司 用于合成喜树碱衍生物的中间体及其制备方法和用途
CN112409281B (zh) * 2020-08-20 2022-11-18 上海大学 (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法
CN112679446A (zh) * 2020-10-26 2021-04-20 都创(上海)医药科技有限公司 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法
WO2022206797A1 (zh) * 2021-03-30 2022-10-06 贝达药业股份有限公司 Egfr抑制剂及其组合物和用途
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
AU2022303386A1 (en) * 2021-07-02 2023-12-14 Aldeyra Therapeutics, Inc. Heterocyclic aldehyde trapping compounds and uses thereof
EP4380924A4 (en) * 2021-08-02 2025-10-01 Dizal Jiangsu Pharmaceutical Co Ltd NEW PHARMACEUTICAL SALTS AND POLYMORPHIC FORMS OF AN ERBB AND BTK INHIBITOR
CN115181093B (zh) * 2022-08-01 2023-04-25 重庆医科大学 Sunvozertinib中间体的制备方法
WO2024261740A1 (en) 2023-06-23 2024-12-26 Assia Chemical Industries, Ltd. Solid state forms of sunvozertinib
WO2025247783A1 (en) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Pesticidally active dihydro-benzoxazinone compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108754A1 (ja) 2012-01-17 2013-07-25 アステラス製薬株式会社 ピラジンカルボキサミド化合物
WO2013138502A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
WO2015003658A1 (en) 2013-07-11 2015-01-15 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
CN105384694A (zh) 2014-08-22 2016-03-09 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106083736A (zh) 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
CN106883213A (zh) 2015-12-15 2017-06-23 合肥中科普瑞昇生物医药科技有限公司 一种新型egfr和alk激酶的双重抑制剂
CN106905245A (zh) 2015-12-23 2017-06-30 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
WO2017114500A1 (zh) 2015-12-31 2017-07-06 恩瑞生物医药科技（上海）有限公司 丙烯酰苯胺衍生物、其制备方法及其药学上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1719762B1 (en) * 2004-02-27 2012-06-27 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (1)
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US20150166591A1 (en) * 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
BR112015010221B1 (pt) 2012-11-06 2022-09-13 Shanghai Fochon Pharmaceutical Co., Ltd. Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento
CN105377835B (zh) * 2013-07-11 2018-08-17 贝达药业股份有限公司 酪氨酸蛋白激酶调节剂及其应用方法
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
KR102782739B1 (ko) * 2018-03-13 2025-03-20 보로노이 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108754A1 (ja) 2012-01-17 2013-07-25 アステラス製薬株式会社 ピラジンカルボキサミド化合物
WO2013138502A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
WO2015003658A1 (en) 2013-07-11 2015-01-15 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
CN105384694A (zh) 2014-08-22 2016-03-09 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106883213A (zh) 2015-12-15 2017-06-23 合肥中科普瑞昇生物医药科技有限公司 一种新型egfr和alk激酶的双重抑制剂
CN106905245A (zh) 2015-12-23 2017-06-30 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
WO2017114500A1 (zh) 2015-12-31 2017-07-06 恩瑞生物医药科技（上海）有限公司 丙烯酰苯胺衍生物、其制备方法及其药学上的应用
CN106083736A (zh) 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024010038A (ja) * 2018-01-31 2024-01-23 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ／ｂｔｋ阻害剤
JP7738619B2 (ja) 2018-01-31 2025-09-12 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ／ｂｔｋ阻害剤

Also Published As

Publication number Publication date
MX2023010411A (es) 2023-09-18
DK3746424T3 (da) 2024-03-25
EP3746424A1 (en) 2020-12-09
RU2764069C1 (ru) 2022-01-13
US20200316079A1 (en) 2020-10-08
WO2019149164A1 (en) 2019-08-08
CN111909131B (zh) 2022-02-15
RU2021139070A (ru) 2022-01-26
JP2024010038A (ja) 2024-01-23
CN111587244A (zh) 2020-08-25
US11504375B2 (en) 2022-11-22
CN111909131A (zh) 2020-11-10
EP3746424B1 (en) 2024-03-06
TWI798334B (zh) 2023-04-11
ES2977484T3 (es) 2024-08-26
CN111747934A (zh) 2020-10-09
AU2019215538A1 (en) 2020-07-09
JP2025179139A (ja) 2025-12-09
AU2019215538B2 (en) 2023-02-02
AU2023202151B2 (en) 2025-01-23
CA3086616A1 (en) 2019-08-08
JP2021512087A (ja) 2021-05-13
KR20250046340A (ko) 2025-04-02
MX2020007947A (es) 2021-02-09
EP4356975A3 (en) 2024-07-24
US11007198B2 (en) 2021-05-18
JP7738619B2 (ja) 2025-09-12
KR102786279B1 (ko) 2025-03-25
BR112020015726A2 (pt) 2020-12-08
TW201940472A (zh) 2019-10-16
PT3746424T (pt) 2024-03-21
AU2023202151A1 (en) 2023-05-04
US20210252005A1 (en) 2021-08-19
EP3746424A4 (en) 2021-08-25
EP4356975A2 (en) 2024-04-24
KR20210013544A (ko) 2021-02-04

Similar Documents

Publication Publication Date Title
JP7738619B2 (ja) Ｅｒｂｂ／ｂｔｋ阻害剤
KR102728940B1 (ko) 암 치료를 위한 n-헤테로방향족 아미드 유도체
AU2011311814B2 (en) Substituted pyridazine carboxamide compounds
JPWO2019189555A1 (ja) 複素環化合物
US11896597B2 (en) ErbB/BTK inhibitors
HK40109818A (en) Erbb/btk inhibitors
BR112020015726B1 (pt) Composto, composição farmacêutica compreendendo o mesmo e seus usos na fabricação de medicamentos
HK40039346B (en) Erbb/btk inhibitors
HK40039346A (en) Erbb/btk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240124

R150 Certificate of patent or registration of utility model

Ref document number: 7427597

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150